Initiation of primary anti-vaccinia virus immunity in vivo

Immunologic Research

Volumn 37, Issue 2, 2007, Pages 113-133

  Fischer, Matthew A ^a   Norbury, Christopher C ^a,b  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

^b PENN STATE MILTON S HERSHEY MEDICAL CENTER   (United States)

Author keywords

T cells; B cells; CD4 T cells; CD8 T cells; Dendritic cells; Macrophages; Neutrophils; NK cells; Vaccinia

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; SMALLPOX VACCINE; VIRUS VECTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; DENDRITIC CELL; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; POXVIRUS; PRIORITY JOURNAL; REVIEW; SMALLPOX; T LYMPHOCYTE; VACCINATION; VACCINIA VIRUS; VIRUS IMMUNITY;

ANIMALS; HUMANS; PRIMATES; SMALLPOX VACCINE; VACCINIA; VACCINIA VIRUS;

EID: 34548302063     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02685894     Document Type: Review

References (145)

1. Marshall E: Gene therapy death prompts review of adenovirus vector. Science 1999; 286:2244-2245.
2. Radetsky M: Smallpox: a history of its rise and fall. Pediatr Infect Dis J 1999; 18:85-93.
3. Downie AW: Immunological relationship of the virus of spontaneous cowpox to vaccinia virus. J Exp Pathol 1939; 20:158-176.
4. Centers for Disease Control and Prevention: Human Monkeypox - Kasai Oriental, Demoncratic Republic of Congo, Feburary 1996-October 1997. MMWR Morb Mortal Wkly 1997; 46:1168-1171.
5. Reed KD, Melski JW, Graham MB, et al: The detection of monkeypox in humans in the Western Hemisphere. N Engl J Med 2004; 350:342-350.
6. Halsell JS, Riddle JR, Atwood JE, et al: Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. JAMA 2003; 289:3283-3289.
7. Fenner F: Smallpox: emergence, global spread, and eradication. Hist Philos Life Sci 1993; 15:397-420.
8. Lane JM, Ruben FL, Neff JM, Millar JD: Complications of smallpox vaccination, 1968. N Engl J Med 1969; 281:1201-1208.
9. Edghill-Smith Y, Golding H, Manischewitz J, et al: Smallpox vaccine-induced antibodies are necessary and sufficient for protection against monkeypox virus. Nat Med 2005; 11:740-747.
10. Earl PL, Americo JL, Wyatt LS, et al: Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004; 428:182-185.
11. Mossman K, Upton C, Buller RM, McFadden G: Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins. Virology 1995; 208:762-769.
12. Alcami A, Smith GL:Vaccinia, cowpox, and camelpox viruses encode soluble gamma interferon receptors with novel broad species specificity. J Virol 1995; 69:4633-4639.
13. Symons JA, Tscharke DC, Price N, Smith GL: A study of the vaccinia virus interferon-gamma receptor and its contribution to virus virulence. J Gen Virol 2002; 83:1953-1964.
14. Tscharke DC, Smith GL: A model for vaccinia virus pathogenesis and immunity based on intradermal injection of mouse ear pinnae. J Gen Virol 1999; 80 (Pt 10):2751-2755.
15. Tscharke DC, Reading PC, Smith GL: Dermal infection with vaccinia virus reveals roles for virus proteins not seen using other inoculation routes. J Gen Virol 2002; 83:1977-1986.
16. Tscharke DC, Karupiah G, Zhou J, et al: Identification of poxvirus CD8+ T cell determinants to enable rational design and characterization of smallpox vaccines. J Exp Med 2005; 201:95-104.
17. Reading PC, Smith GL: A kinetic analysis of immune mediators in the lungs of mice infected with vaccinia virus and comparison with intradermal infection. J Gen Virol 2003; 84:1973-1983.
18. Jacobs N, Chen RA, Gubser C, Najarro P, Smith GL: Intradermal immune response after infection with vaccinia virus. J Gen Virol 2006; 87:1157-1161.
19. Hume DA, Robinson AP, MacPherson GG, Gordon S: The mononuclear phagocyte system of the mouse defined by immunohistochemical localization of antigen F4/80. Relationship between macrophages, Langerhans cells, reticular cells, and dendritic cells in lymphoid and hematopoietic organs. J Exp Med 1983; 158:1522-1536.
20. Ginhoux F, Tacke F, Angeli V, et al: Langerhans cells arise from monocytes in vivo. Nat Immunol 2006; 7:265-273.
21. Nishmi M, Bernkopf H: The toxic effect of vaccinia virus on leucocytes in vitro. J Immunol 1958; 81:460-466.
22. Natuk RJ, Holowczak JA: Vaccinia virus proteins on the plasma membrane of infected cells. III. Infection of peritoneal macrophages. Virology 1985; 147:354-372.
23. Broder CC, Kennedy PE, Michaels F, Berger EA: Expression of foreign genes in cultured human primary macrophages using recombinant vaccinia virus vectors. Gene 1994; 142:167-174.
24. Beard JW, Rous PJ: The fate of vaccinia virus on cultivation in vitro with Kupffer cells (RE cells). J Exp Med 1938; 67:883-910.
25. Tompkins WA, Zarling JM, Rawls WE: In vitro assessment of cellular immunity to vaccinia virus: contribution of lymphocytes and macrophages. Infect Immun 1970; 2:783-790.
26. Avila FR, Schultz RM, Tompkins WA: Specific macrophage immunity to vaccinia virus: macrophage-virus interaction. Infect Immun 1972; 6:9-16.
27. McLaren C, Cheng H, Spicer DL, Tompkins WA: Lymphocyte and macrophage responses after vaccinia virus infections. Infect Immun 1976; 14:1014-1021.
28. Greer B, Delfs D, McElree H: Electron microscope study of the interaction of vaccinia virus with macrophages from immunized and nonimmunized rabbits. Infect Immun 1974; 9:452-459.
29. Ueda S, Nozima T: Delayed hypersensitivity in vaccinia-infected mice. II. Resistance of peritoneal macrophages against vaccinia infection. Acta Virol 1973; 17:41-49.
30. Koszinowski U, Kruse F, Thomssen R: Interactions between vaccinia virus and sensitized macrophages in vitro. Arch Virol 1975; 48:335-345.
31. Buchmeier NA, Gee SR, Murphy FA, Rawls WE: Abortive replication of vaccinia virus in activated rabbit macrophages. Infect Immun 1979; 26:328-338.
32. Rodriguez JR, Rodriguez D, Esteban M: Interferon treatment inhibits early events in vaccinia virus gene expression in infected mice. Virology 1991; 185:929-933.
33. Karupiah G, Xie QW, Buller RM, Nathan C, Duarte C, MacMicking JD: Inhibition of viral replication by interferon-gamma-induced nitric oxide synthase. Science 1993; 261:1445-1448.
34. Melkova Z, Esteban M: Interferon-gamma severely inhibits DNA synthesis of vaccinia virus in a macrophage cell line. Virology 1994; 198:731-735.
35. Harris N, Buller RM, Karupiah G: Gamma interferon-induced, nitric oxide-mediated inhibition of vaccinia virus replication. J Virol 1995; 69:910-915.
36. Karupiah G, Harris N: Inhibition of viral replication by nitric oxide and its reversal by ferrous sulfate and tricarboxylic acid cycle metabolites. J Exp Med 1995; 181:2171-2179.
37. van Rooijen N, Sanders A: Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 1994; 174:83-93.
38. Nakano H, Yanagita M, Gunn MD: CD11c(+)B220(+) Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. J Exp Med 2001; 194:1171-1178.
39. West BC, Eschete ML, Cox ME, King JW: Neutrophil uptake of vaccinia virus in vitro. J Infect Dis 1987; 156:597-606.
40. Jones JF: Interactions between human neutrophils and vaccinia virus: induction of oxidative metabolism and virus inactivation. Pediatr Res 1982; 16:525-529.
41. Moss B: Poxvirus entry and membrane fusion. Virology 2006; 344:48-54.
42. Natuk RJ, Welsh RM: Accumulation and chemotaxis of natural killer/large granular lymphocytes at sites of virus replication. J Immunol 1987; 138:877-883.
43. Prlic M, Gibbs J, Jameson SC: Characteristics of NK cell migration early after vaccinia infection. J Immunol 2005; 175:2152-2157.
44. Brutkiewicz RR, Klaus SJ, Welsh RM: Window of vulnerability of vaccinia virus-infected cells to natural killer (NK) cell-mediated cytolysis correlates with enhanced NK cell triggering and is concomitant with a decrease in H-2 antigen expression. 1992; 11:203-214.
45. Bottino C, Castriconi R, Moretta L, Moretta A: Cellular ligands of activating NK receptors. Trends Immunol 2005; 26:221-226.
46. Chisholm SE, Reyburn HT: Recognition of vaccinia virus-infected cells by human natural killer cells depends on natural cytotoxicity receptors. J Virol 2006; 80:2225-2233.
47. Bukowski JF, Morita CT, Brenner MB: Recognition and destruction of virus-infected cells by human gamma-delta CTL. J Immunol 1994; 153:5133-5140.
48. Kennedy MK, Glaccum M, Brown SN, et al: Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J Exp Med 2000; 191:771-780.
49. Prlic M, Blazar BR, Farrar MA, Jameson SC: In vivo survival and homeostatic proliferation of natural killer cells. J Exp Med 2003; 197:967-976.
50. Stitz L, Baenziger J, Pircher H, Hengartner H, Zinkernagel RM: Effect of rabbit anti-asialo GM1 treatment in vivo or with anti-asialo GM1 plus complement in vitro on cytotoxic T cell activities. J Immunol 1986; 136:4674-4680.
51. Welsh RM, Lin MY, Lohman BL, Varga SM, Zarozinski CC, Selin LK: Alpha beta and gamma delta T-cell networks and their roles in natural resistance to viral infections. Immunol Rev 1997; 159:79-93.
52. Selin LK, Santolucito PA, Pinto AK, Szomolanyi-Tsudá E, Welsh RM: Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001; 166:6784-6794.
53. Glasgow LA, Habel K: The role of interferon in vaccinia virus infection of mouse embryo tissue culture. J Exp Med 1962; 115:503-512.
54. Diebold SS, Montoya M, Unger H, et al:Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003; 424:324-328.
55. Colamonici OR, Domanski P, Sweitzer SM, Larner A, Buller RM: Vaccinia virus B18R gene encodes a type I interferon-binding protein that blocks interferon alpha transmembrane signaling. J Biol Chem 1995; 270:15974-15978.
56. Symons JA, Alcami A, Smith GL: Vaccinia virus encodes a soluble type 1 interferon receptor of novel structure and broad species specificity. 1995; 81:551-560.
57. Liptakova H, Kontsekova E, Alcami A, Smith GL, Kontsek P: Analysis of an interaction between the soluble vaccinia virus-coded type I interferon (IFN)-receptor and human IFN-alpha1 and IFN-alpha2. Virology 1997; 232:86-90.
58. van den Broek MF, Muller U, Huang S, Zinkernagel RM, Aguet M: Immune defence in mice lacking type I and/or type II interferon receptors. Immunol Rev 1995; 148:5-18.
59. Kohonen-Corish MR, King NJ, Woodhams CE, Ramshaw, IA: Immunodeficient mice recover from infection with vaccinia virus expressing interferon-gamma. Eur J Immunol 1990; 20:157-161.
60. Huang S, Hendriks W, Althage A, et al: Immune response in mice that lack the interferon-gamma receptor. Science 1993; 259:1742-1745.
61. Bartlett NW, Buttigieg K, Kotenko SV, Smith GL: Murine interferon lambdas (type III interferons) exhibit potent antiviral activity in vivo in a poxvirus infection model. J Gen Virol 2005; 86:1589-1596.
62. Xu R, Johnson AJ, Liggitt D, Bevan MJ: Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004; 172:6265-6271.
63. Davies DH, McCausland MM, Valdez C, et al:Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol 2005; 79:11724-11733.
64. Law M, Putz MM, Smith GL: An investigation of the therapeutic value of vaccinia-immune IgG in a mouse pneumonia model. J Gen Virol 2005; 86:991-1000.
65. Lustig S, Fogg C, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B: Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge. J Virol 2005; 79:13454-13462.
66. Shearer JD, Siemann L, Gerkovich M, House RV: Biological activity of an intravenous preparation of human vaccinia immune globulin in mouse models of vaccinia virus infection. Antimicrob Agents Chemother 2005; 49:2634-2641.
67. Wherry EJ, Rajagopal D, Eisenlohr LC: Use of vaccinia virus expression vectors to investigate antigen processing and presentation. Methods Mol Biol 2001; 156:89-109.
68. Amanna IJ, Slifka MK, Crotty S: Immunity and immunological memory following smallpox vaccination. Immunol Rev 2006; 211:320-337.
69. Zinkernagel RM, Althage A: Antiviral protection by virus-immune cytotoxic T cells: infected target cells are lysed before infectious virus progeny is assembled. J Exp Med 1977; 145:644-651.
70. Harrington LE, Most Rv R, Whitton JL, Ahmed R: Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J Virol 2002; 76:3329-3337.
71. Spriggs MK, Koller BH, Sato T, et al: Beta 2-microglobulin-, CD8+ T-cell-deficient mice survive inoculation with high doses of vaccinna virus and exhibit altered IgG responses. Proc Natl Acad Sci USA 1992; 89:6070-6074.
72. Belyakov IM, Earl P, Dzutsev A, et al: Shared modes of protection against poxvirus infection by attenuated and conventional smallpox vaccine viruses. Proc Natl Acad Sci USA 2003; 100:9458-9463.
73. Terajima M, Cruz J, Raines G, et al: Quantitation of CD8+ T cell responses to newly identified HLAA* 0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003; 197:927-932.
74. Drexler I, Staib C, Kastenmuller W, et al: Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 2003; 100:217-222.
75. Snyder JT, Belyakov IM, Dzutsev A, Lemonnier F, Berzofsky JA: Protection against lethal vaccinia virus challenge in HLA-A2 transgenic mice by immunization with a single CD8+ T-cell peptide epitope of vaccinia and variola viruses. J Virol 2004; 78:7052-7060.
76. Mathew A, Terajima M, West K, et al: Identification of murine poxvirus-specific CD8+ CTL epitopes with distinct functional profiles. J Immunol 2005; 174:2212-2219.
77. Pasquetto V, Bui HH, Giannino R, et al: HLA-A*0201, HLA-A*1101, and HLA-B*0702 transgenic mice recognize numerous poxvirus determinants from a wide variety of viral gene products. J Immunol 2005; 175:5504-5515.
78. Oseroff C, Kos F, Bui HH, et al: HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 2005; 102:13980-13985.
79. Terajima M, Cruz J, Leporati AM, Demkowicz WE Jr, Kennedy JS, Ennis FA: Identification of vaccinia CD8+ T-cell epitopes conserved among vaccinia and variola viruses restricted by common MHC class I molecules, HLA-A2 or HLA-B7. Hum Immunol 2006; 67:512-520.
80. Hanada K, Yewdell JW, Yang JC: Immune recognition of a human renal cancer antigen through post-translational protein splicing. Nature 2004; 427:252-256.
81. Sette A, Vitiello A, Reherman B, et al: The relationship between class I binding affinity and immunologenicity of potential cytotoxic T cell epotopes. J Immunol 1994; 153:5586-5592.
82. Vitiello A, Yuan L, Chesnut RW, et al: Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol 1996; 157:5555-5562.
83. Tscharke DC, Woo WP, Sakala IG, et al: Poxvirus CD8+ T-cell determinants and cross-reactivity in BALB/c mice. J Virol 2006; 80:6318-6323.
84. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998; 392:245-252.
85. Bontkes HJ, Ruizendaal JJ, Schreurs MW, Kramer D, Meijer CJ, Hooijberg E: Antigen gene transfer to human plasmacytoid dendritic cells using recombinant adenovirus and vaccinia virus vectors. Cell Oncol 2005; 27:175-182.
86. Princiotta MF, Finzi D, Qian SB, et al: Quantitating protein synthesis, degradation, and endogenous antigen processing. Immunity 2003; 18:343-354.
87. Bronte V, Carroll MW, Goletz TJ, et al: Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci USA 1997; 94:3183-3188.
88. Engelmayer J, Larsson M, Subklewe M, et al:Vaccinia virus inhibits the maturation of human dendritic cells: a novel mechanism of immune evasion. J Immunol 1999; 163:6762-6768.
89. Engelmayer J, Larsson M, Lee A, et al: Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 2001; 75:2142-2153.
90. Larsson M, Fonteneau JF, Somersan S, et al: Efficiency of cross presentation of vaccinia virus-derived antigens by human dendritic cells. Eur J Immunol 2001; 31:3432-3442.
91. Becker Y, Sprecher E: Langerhans cells in vaccinia virus infection in mouse skin. Arch Virol 1989; 107:307-313.
92. He Y, Zhang J, Donahue C, Falo LD Jr: Skin-derived dendritic cells induce potent CD8(+) T cell immunity in recombinant lentivector-mediated genetic immunization. Immunity 2006; 24:643-656.
93. Norbury CC, Malide D, Gibbs JS, Bennink JR, Yewdell JW: Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo. Nat Immunol 2002; 3:265-271.
94. Belz GT, Smith CM, Eichner D, et al: Cutting edge: conventional CD8alpha(+) dendritic cells are generally involved in priming CTL immunity to viruses. J Immunol 2004; 172:1996-2000.
95. Lanzavecchia A, Reid PA, Watts C: Irreversible association of peptides with class II MHC molecules in living cells. Nature 1992; 357:249-252.
96. Pinet VM, Long EO: Peptide loading onto recycling HLA-DR molecules occurs in early endosomes. Eur J Immunol 1998; 28:799-804.
97. Busch R, Cloutier I, Sekaly RP, Hammerling GJ: Invariant chain protects class II histocompatibility antigens from binding intact polypeptides in the endoplasmic reticulum. EMBO J 1996; 15:418-428.
98. Malnati MS, Marti M, LaVaute T, et al: Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells. Nature 1992; 357:702-704.
99. Malnati MS, Ceman S, Weston M, DeMars R, and Long EO: Presentation of cytosolic antigen by HLA-DR requires a function encoded in the class II region of the MHC. J Immunol 1993; 151:6751-6756.
100. Oxenius A, Bachmann MF, Ashton-Rickardt PG, Tonegawa S, Zinkernagel RM, Hengarter H: Presentation of endogenous viral proteins in association with major histocompatibility complex class II: on the role of intracellular compartmentalization, invariant chain and the TAP transporter system. Eur J Immunol 1995; 25:3402-3411.
101. Basta S, Chen W, Bennink JR, Yewdell JW: Inhibitory effects of cytomegalovirus proteins US2 and US11 point to contributions from direct priming and cross-priming in induction of vaccinia virus-specific CD8(+) T cells. J Immunol 2002; 168:5403-5408.
102. Shen X, Wong SB, Buck CB, Zhang J, Siliciano RF: Direct priming and cross-priming contribute differentially to the induction of CD8+ CTL following exposure to vaccinia virus via different routes. J Immunol 2002; 169:4222-4229.
103. Yewdell JW, Bennink JR: Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999; 17:51-88.
104. Smith CL, Mirza F, Pasquetto V, et al: Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005; 175:8431-8437.
105. Smith GL, Symons JA, Alcami A: Immune modulation by proteins secreted from cells infected by vaccinia virus. Arch Virol Suppl 1999; 15:111-129.
106. Wyatt LS, Earl PL, Eller LA, Moss B: Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci USA 2004; 101:4590-4595.
107. Sutter G, Moss B: Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev Biol Stand 1995; 84:195-200.
108. Staib C, Kisling S, Erfle V, Sutter G: Inactivation of the viral interleukin 1beta receptor improves CD8+ T-cell memory responses elicited upon immunization with modified vaccinia virus Ankara. J Gen Virol 2005; 86:1997-2006.
109. Clark RH, Kenyon JC, Bartlett NW, Tscharke DC, Smith GL: Deletion of gene A41L enhances vaccinia virus immunogenicity and vaccine efficacy. J Gen Virol 2006; 87:29-38.
110. Coupar BE, Andrew ME, Both GW, Boyle DB: Temporal regulation of influenza hemagglutinin expression in vaccinia virus recombinants and effects on the immune response. Eur J Immunol 1986; 16:1479-1487.
111. Hodge JW, Abrams S, Schlom J, Kantor, JA: Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Cancer Res 1994; 54:5552-5555.
112. Hodge JW, McLaughlin JP, Abrams SI, Shupert WL, Schlom J, Kantor JA: Admixture of a recombinant vaccinia virus containing the gene for the costimulatory molecule B7 and a recombinant vaccinia virus containing a tumor-associated antigen gene results in enhanced specific T-cell responses and antitumor immunity. Cancer Res 1995; 55:3598-3603.
113. Chamberlain RS, Carroll MW, Bronte V, et al: Costimulation enhances the active immunotherapy effect of recombinant anticancer vaccines. Cancer Res 1996; 56:2832-2836.
114. Kaufman HL, Deraffele G, Mitcham J, et al: Targeting the local tumor microenvironment with vaccinia virus expressing B7.1 for the treatment of melanoma. J Clin Invest 2005; 115:1903-1912.
115. Marti WR, Oertli D, Meko JB, Norton JA, Tsung K: Induction of antigen-presenting capacity in tumor cells upon infection with non-replicating recombinant vaccinia virus encoding murine MHC class II and costimulatory molecules. J Immunol Methods 1997; 200:191-198.
116. Oertli D, Marti WR, Norton JA, Tsung K: Artificial antigen-presenting cells engineered by recombinant vaccinia viruses expressing antigen, MHC class II, and costimulatory molecules elicit proliferation of CD4+ lymphocytes in vitro. Clin Exp Immunol 1997; 110:144-149.
117. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J: A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res 1999; 59:5800-5807.
118. Hodge JW, Grosenbach DW, Rad AN, Giuliano M, Sabzevari H, Schlom J: Enhancing the potency of peptide-pulsed antigen presenting cells by vector-driven hyperexpression of a triad of costimulatory molecules. Vaccine 2001; 19:3552-3567.
119. Kudo-Saito C, Schlom J, Hodge, JW: Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules. Clin Cancer Res 2004; 10:1090-1099.
120. Marshall JL, Gulley JL, Arlen PM, et al: Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 2005; 23:720-731.
121. Dipaola R, Plante M, Kaufman H, et al: A phase I trial of pox PSA vaccines (PROSTVAC(R)-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in patients with prostate cancer. J Transl Med 2006; 4:1.
122. Garnett CT, Greiner JW, Tsang KY, et al: TRICOM vector based cancer vaccines. Curr Pharm Des 2006; 12:351-361.
123. Kudo-Saito C, Hodge JW, Kwak H, Kim-Schulze S, Schlom J, Kaufman HL: 4-1BB ligand enhances tumor-specific immunity of poxvirus vaccines. Vaccine 2006; 24:4975-4986.
124. Lorenz MG, Kantor JA, Schlom J, Hodge, JW: Antitumor immunity elicited by a recombinant vaccinia virus expressing CD70 (CD27L). Hum Gene Ther 1999; 10:1095-1103.
125. Ramshaw IA, Andrew ME, Phillips SM, Boyle DB, Coupar BE: Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection. Nature 1987; 329:545-546.
126. Flexner C, Hugin A, Moss B: Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression. Nature 1987; 330:259-262.
127. Karupiah G, Blanden RV, Ramshaw IA: Interferon gamma is involved in the recovery of athymic nude mice from recombinant vaccinia virus/interleukin 2 infection. J Exp Med 1990; 172:1495-1503.
128. Ruby J, Fordham S, Kasprzak A, Osvath S, Ramshaw, I: The immunobiology of murine interleukin-1 alpha encoded by recombinant vaccinia virus. Cytokine 1991; 3:92-97.
129. Peplinski GR, Tsung K, Whitman ED, Meko JB, Norton JA: Construction and expression in tumor cells of a recombinant vaccinia virus encoding human interleukin-1 beta. Ann Surg Oncol 1995; 2:151-159.
130. Ramsay AJ, Kohonen-Corish M: Interleukin-5 expressed by a recombinant virus vector enhances specific mucosal IgA responses in vivo. Eur J Immunol 1993; 23:3141-3145.
131. Ramsay AJ, Husband AJ, Ramshaw IA, et al: The role of interleukin-6 in mucosal IgA antibody responses in vivo. Science 1994; 264:561-563.
132. Kurilla MG, Swaminathan S, Welsh RM, Kieff E, Brutkiewicz RR: Effects of virally expressed interleukin-10 on vaccinia virus infection in mice. J Virol 1993; 67:7623-7628.
133. Meko JB, Tsung K, Norton JA: Cytokine production and antitumor effect of a nonreplicating, noncytopathic recombinant vaccinia virus expressing interleukin-12. Surgery 1996; 120:274-282; discussion 282-283.
134. Patera AC, Pesnicak L, Bertin J, Cohen, JI: Interleukin 17 modulates the immune response to vaccinia virus infection. Virology 2002; 299:56-63.
135. Qin H, Chatterjee SK: Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996; 7:1853-1860.
136. Sambhi SK, Kohonen-Corish MR, Ramshaw IA: Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci USA 1991; 88:4025-4029.
137. Andrew ME, Coupar BEH: Biological effects of recombinant vaccinia virus-expressed interleukin 4. Cytokine 1992; 4:281-286.
138. Sharma DP, Ramsay AJ, Maguire DJ, Rolph MS, Ramshaw IA: Interleukin-4 mediates down regulation of antiviral cytokine expression and cytotoxic T-lymphocyte responses and exacerbates vaccinia virus infection in vivo. J Virol 1996; 70:7103-7107.
139. Esteban DJ, Buller RM: Ectromelia virus: the causative agent of mousepox. J Gen Virol 2005; 86:2645-2659.
140. Karupiah G, Buller RM, Van Rooijen N, Duarte CJ, Chen J: Different roles for CD4+ and CD8+ T lymphocytes and macrophage subsets in the control of a generalized virus infection. J Virol 1996; 70:8301-8309.
141. Jackson RJ, Ramsay AJ, Christensen CD, Beaton S, Hall DF, Ramshaw IA: Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox. J Virol 2001; 75:1205-1210.
142. Mullbacher A, Lobigs M: Creation of killer poxvirus could have been predicted. J Virol 2001; 75:8353-8355.
143. Aung S, Graham BS: IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity In vivo. J Immunol 2000; 164:3487-3493.
144. Kagi D, Seiler P, Pavlovic J, et al: The roles of perforinand Fas-dependent cytotoxicity in protection against cytopathic and noncytopathic viruses. Eur J Immunol 1995; 25:3256-3262.
145. Mullbacher A, Hla RT, Museteanu C, Simon MM: Perforin is essential for control of ectromelia virus but not related poxviruses in mice. J Virol 1999; 73:1665-1667.